Literature DB >> 28115102

Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review.

Yishu Yan1, Yang Ji2, Nan Su3, Xiang Mei4, Yi Wang5, Shanshan Du6, Wenming Zhu7, Chong Zhang8, Yuan Lu9, Xin-Hui Xing10.   

Abstract

Low molecular weight heparins (LMWHs) are produced by chemical or enzymatic depolymerization of unfractionated heparin (UFH). Besides their well-known anticoagulant effects, LMWHs have also been reported to exhibit numerous anti-inflammatory properties. Previous studies have, however, shown that different production processes result in unique structural characteristics of LMWHs. The structural variations may help explain the different therapeutic spectrums in disease treatment for non-anticoagulant effects. In the present review, we summarize major advances in understanding and exploiting the anti-inflammatory disorder activities of LMWHs, based on mechanistic studies, preclinical experiments and clinical trials. We highlight differences in these activities of commercially available LMWHs produced using different manufacturing processes. We stress the importance of structure-activity relationship (SAR) studies on the non-anticoagulant effects of LMWHs and discuss strategies for exploring new clinical indications.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Heparin; Inflammation; Low molecular weight heparins; Non-anticoagulant

Mesh:

Substances:

Year:  2016        PMID: 28115102     DOI: 10.1016/j.carbpol.2016.12.037

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  9 in total

1.  Heparin Protects Severe Acute Pancreatitis by Inhibiting HMGB-1 Active Secretion from Macrophages.

Authors:  Jing Yang; Xujiao Tang; Qingqing Wu; Panpan Ren; Yishu Yan; Wei Liu; Chun Pan
Journal:  Polymers (Basel)       Date:  2022-06-17       Impact factor: 4.967

Review 2.  Drug delivery carriers with therapeutic functions.

Authors:  Shuting S Cai; Tianyu Li; Tolulope Akinade; Yuefei Zhu; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2021-07-21       Impact factor: 17.873

3.  Effects of Enzymatically Depolymerized Low Molecular Weight Heparins on CCl4-Induced Liver Fibrosis.

Authors:  Yishu Yan; Changge Guan; Shanshan Du; Wenming Zhu; Yang Ji; Nan Su; Xiang Mei; Dong He; Yuan Lu; Chong Zhang; Xin-Hui Xing
Journal:  Front Pharmacol       Date:  2017-08-21       Impact factor: 5.810

Review 4.  Polysaccharide-Based Materials Created by Physical Processes: From Preparation to Biomedical Applications.

Authors:  Paulo R Souza; Ariel C de Oliveira; Bruno H Vilsinski; Matt J Kipper; Alessandro F Martins
Journal:  Pharmaceutics       Date:  2021-04-27       Impact factor: 6.321

Review 5.  Role of heparinase in the gastrointestinal dysfunction of sepsis (Review).

Authors:  Ting-Ting Chen; Jia-Jun Lv; Ling Chen; Yu-Wei Gao; Li-Ping Liu
Journal:  Exp Ther Med       Date:  2021-12-06       Impact factor: 2.447

Review 6.  The beneficial role of Hepcidin peptide inhibitor in improved the symptoms of COVID-19 in diabetics: anti-inflammatory and potential therapeutic effects.

Authors:  Motahareh Zeinivand; Nida Jamali-Raeufy; Fahime Zavvari
Journal:  J Diabetes Metab Disord       Date:  2022-07-06

Review 7.  Heparin Mimetics: Their Therapeutic Potential.

Authors:  Shifaza Mohamed; Deirdre R Coombe
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-02

Review 8.  Advanced delivery strategies facilitating oral absorption of heparins.

Authors:  Guihua Fang; Bo Tang
Journal:  Asian J Pharm Sci       Date:  2020-01-09       Impact factor: 6.598

Review 9.  Comprehensive Landscape of Heparin Therapy for COVID-19.

Authors:  Chen Shi; Wu Tingting; Jin-Ping Li; Mitchell A Sullivan; Cong Wang; Hanxiang Wang; Bin Deng; Yu Zhang
Journal:  Carbohydr Polym       Date:  2020-10-22       Impact factor: 10.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.